Uroplasty (NASDAQ: UPI) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Uroplasty to similar companies based on the strength of its valuation, risk, earnings, analyst recommendations, profitability, dividends and institutional ownership.

Insider & Institutional Ownership

54.8% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Uroplasty and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uroplasty 0 0 0 0 N/A
Uroplasty Competitors 112 732 1028 10 2.50

As a group, “Medical Devices & Implants” companies have a potential upside of 38.02%. Given Uroplasty’s competitors higher probable upside, analysts plainly believe Uroplasty has less favorable growth aspects than its competitors.

Profitability

This table compares Uroplasty and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Uroplasty -31.58% -87.33% -60.82%
Uroplasty Competitors -101.23% -92.70% -30.32%

Valuation and Earnings

This table compares Uroplasty and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Uroplasty N/A N/A -4.07
Uroplasty Competitors $1.67 billion $207.58 million 82.50

Uroplasty’s competitors have higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Uroplasty has a beta of -1.26, meaning that its stock price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s competitors have a beta of 0.95, meaning that their average stock price is 6% less volatile than the S&P 500.

Summary

Uroplasty competitors beat Uroplasty on 6 of the 8 factors compared.

About Uroplasty

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.